| Literature DB >> 28096812 |
Erdal Benli1, Abdullah Cirakoglu1, Ercan Ogreden2, Yeliz Cetinkol3, Mustafa Kerem Calgin3, Ali Ayyildiz1, Ahmet Yüce1.
Abstract
Aim. The aim of this study is to evaluate whether leaving the biopsy needle used during prostate needle biopsy in 10% povidone-iodine (betadine) solution affects the infectious complications forming after biopsy. Material and Method. This study retrospectively evaluated the data of 176 patients with prostate biopsy performed between December 2012 and April 2014. Patients in Group 1 (n = 89) were given ofloxacin as a prophylactic antibiotic before biopsy. Patients in Group 2 (n = 87) had the biopsy needle left in povidone-iodine solution for 1 minute before each use, in addition to antibiotic prophylaxis. The two groups were compared in terms of infective complications developing after biopsy. Results were analyzed using the Mann-Whitney U test and Fisher's exact test. Results. The distribution of infective complications after biopsy according to group was as follows. Group 1, not using betadine, had 15.7% fever, 13.5% hospital stay, 12.4% urinary retention, 10.1% prostatitis, and 5.6% sepsis. The distribution of the same complications in Group 2 using betadine was identified as 5.7% fever, 4.6% hospital stay, 3.4% urinary retention, 2.3% prostatitis, and 0% sepsis. The use of betadine was found to significantly reduce the infectious complications after biopsy compared to the control group (p < 0.05). Conclusion. At the end of this study leaving the prostate needle in povidone-iodine solution before each use during prostate biopsy was found to reduce the infective complications and hospital stay after biopsy.Entities:
Year: 2016 PMID: 28096812 PMCID: PMC5206407 DOI: 10.1155/2016/6841837
Source DB: PubMed Journal: Adv Urol ISSN: 1687-6369
Characteristics of patients in the groups.
| Characteristic | Group 1 ( | Group 2 ( |
|
|---|---|---|---|
| Age (y), mean ± SD (range) | 65.4 ± 8.7 (41–88) | 65.3 ± 8.6 (48–86) | 0.812 |
| Diabetes mellitus | 18 (20.2) | 25 (28.7) | 0.221 |
| Waist circumference | 39 (43.8) | 45 (5.7) | 0.294 |
| Hypertension | 25 (28.1) | 30 (34.5) | 0.360 |
| Metabolic syndrome | 32 (36) | 35 (40.2) | 0.559 |
| Heart disease | 18 (20.2) | 15 (17.2) | 0.612 |
| Smoker (%) | 35 (39.3) | 33 (37.9) | 0.849 |
| LUTS | 31 (34.8) | 35 (40.2) | 0.460 |
| Previous history of biopsy | 18 (20.2) | 17 (19.5) | 0.909 |
| PSA level (ng/mL), median (min–max) | 7.20 (2.28–100) | 6.70 (0–150) | 0.293 |
| Prostate volume median (min–max) | 50 (13–153) | 45 (8–131) | 0.224 |
| PVR median (min–max) | 15 (0–300) | 15 (0–433) | 0.494 |
Distribution of complications according to groups.
| Characteristic | Group 1 ( | Group 2 ( |
|
|---|---|---|---|
| Fever | 14 (15.7) | 5 (5.7) | 0.033 |
| Temperature (°C) (mean ± SD) (range) | 38.7 ± 0.9 (37.7–40.2) | 39.3 ± 0.6 (38.7–40) | 0.22 |
| Sepsis | 5 (5.6) | 0 (0) | 0.025 |
| Prostatitis | 9 (10.1) | 2 (2.3) | 0.032 |
| Urinary retention | 11 (12.4) | 3 (3.4) | 0.029 |
| Hospital stay | 12 (13.5) | 4 (4.6) | 0.040 |
| General complications | 26 (29.2) | 7 (8) | <0.001 |
Distribution of bacteria in urine and blood culture according to groups.
| Characteristic | Group 1 ( | Group 2 ( |
|---|---|---|
| Urine culture | ||
| | 15 (%57) | 5 (%71) |
| Quinolone resistance (%) | 10 (%66.6) | 4 (%80) |
| ESBL (%) | 6 (%40) | 3 (%60) |
| Blood culture | ||
| | 5 (%19) | 0 |
| Quinolone resistance (%) | 5 (%100) | 0 |
| ESBL (%) | 4 (%80) | 0 |
ESBL, extended spectrum beta-lactamase.